| |
| |
|
| Insider
Information: |
Pfizer Inc |
| Relationship: |
10% Owner |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
16 |
|
| Direct
Shares |
139,025,200 |
|
|
Indirect Shares
|
102,923,921 |
|
|
| Direct
Value |
$1,176,285,582 |
|
|
|
Indirect Value
|
$123,922,254 |
|
|
| Total
Shares |
241,949,121 |
|
|
| Total
Value |
$1,300,207,836 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 111.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Arqule Inc |
ARQL |
10% Owner |
2003-12-17 |
0 |
2003-12-17 |
3,273,679 |
Premium* |
|
|
EyePoint Pharmaceuticals Inc |
EYPT |
10% Owner |
2007-08-27 |
74,483,748 |
|
0 |
Premium* |
|
|
Coley Pharmaceutical Group, Inc. |
COLY |
10% Owner |
|
0 |
2007-12-28 |
24,423,732 |
Premium* |
|
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-02 |
1,067,015 |
2011-09-02 |
4,611,921 |
Premium* |
|
|
Encysive Pharmaceuticals Inc |
ENCY |
10% Owner |
2008-04-01 |
0 |
2008-04-14 |
69,076,466 |
Premium* |
|
|
Zoetis Inc. |
ZTS |
10% Owner |
2013-06-24 |
0 |
|
0 |
Premium* |
|
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
|
0 |
2013-09-17 |
1,538,123 |
Premium* |
|
|
Celladon Corp |
CLDN |
10% Owner |
2014-02-04 |
1,794,803 |
2014-02-04 |
0 |
Premium* |
|
|
Flexion Therapeutics Inc |
FLXN |
10% Owner |
2014-02-18 |
1,687,250 |
2014-02-18 |
0 |
Premium* |
|
|
Neurogene |
NGNE |
10% Owner |
2015-08-10 |
975,403 |
2014-03-12 |
0 |
Premium* |
|
|
Synlogic Inc |
SYBX |
10% Owner |
2015-10-06 |
2,489,364 |
2015-10-05 |
0 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
10% Owner |
2018-10-15 |
22,032,040 |
2018-10-15 |
0 |
Premium* |
|
|
Upjohn Inc |
VTRS |
10% Owner |
2020-11-16 |
0 |
|
0 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
10% Owner |
2020-10-27 |
26,149,211 |
2020-10-27 |
0 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
10% Owner |
2022-12-23 |
5,376,344 |
|
0 |
Premium* |
|
|
Zura Bio Ltd |
ZURA |
10% Owner |
2023-03-20 |
2,970,022 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ZURA |
Zura Bio Ltd |
10% Owner |
– – • |
2023-03-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,970,022 |
|
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
10% Owner |
– – • |
2022-12-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,376,344 |
|
- |
|
| VTRS |
Upjohn Inc |
10% Owner |
– – • |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(689,874,047) |
0 |
0 |
- |
|
| VTRS |
Upjohn Inc |
10% Owner |
– – • |
2020-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
689,873,947 |
689,874,047 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
10% Owner |
– – • |
2020-10-27 |
4 |
B |
$10.00 |
$12,000,000 |
D/D |
1,200,000 |
27,349,211 |
2.45 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
10% Owner |
– – • |
2020-10-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,149,211 |
|
% |
|
| VTRS |
Upjohn Inc |
10% Owner |
– – • |
2020-08-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100 |
|
- |
|
| ALLO |
Allogene Therapeutics, In... |
10% Owner |
– – • |
2018-10-15 |
4 |
B |
$18.00 |
$1,000,008 |
D/D |
55,556 |
22,032,040 |
2.45 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
10% Owner |
– – • |
2018-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,976,484 |
21,976,484 |
0 |
- |
|
| SYBX |
Synlogic Inc |
10% Owner |
• • • |
2015-10-06 |
4 |
A |
$7.00 |
$1,650,985 |
D/D |
235,855 |
2,489,364 |
0 |
- |
|
| SYBX |
Synlogic Inc |
10% Owner |
• • • |
2015-10-06 |
4 |
B |
$7.00 |
$4,999,995 |
D/D |
714,285 |
2,253,509 |
2.45 |
- |
|
| SYBX |
Synlogic Inc |
10% Owner |
• • • |
2015-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,539,224 |
1,539,224 |
0 |
- |
|
| NGNE |
Neurogene |
10% Owner |
• • • |
2015-08-10 |
4 |
S |
$20.35 |
$6,880,295 |
D/D |
(259,927) |
975,403 |
0 |
- |
|
| NGNE |
Neurogene |
10% Owner |
– – • |
2014-03-12 |
4 |
B |
$11.00 |
$2,999,997 |
D/D |
272,727 |
1,235,330 |
2.45 |
- |
|
| NGNE |
Neurogene |
10% Owner |
– – • |
2014-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
962,603 |
962,603 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
10% Owner |
– – • |
2014-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,687,250 |
1,687,250 |
0 |
- |
|
| CLDN |
Celladon Corp |
10% Owner |
– – • |
2014-02-04 |
4 |
B |
$8.00 |
$1,818,088 |
D/D |
227,261 |
1,794,803 |
2.45 |
- |
|
| CLDN |
Celladon Corp |
10% Owner |
– – • |
2014-02-04 |
4 |
A |
$0.00 |
$185,160 |
D/D |
1,567,542 |
1,567,542 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
10% Owner |
– – • |
2013-09-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,538,123 |
|
- |
|
| ZTS |
Zoetis Inc. |
10% Owner |
– – • |
2013-06-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(400,985,000) |
0 |
0 |
- |
|
| ZTS |
Zoetis Inc. |
10% Owner |
– – • |
2013-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
400,985,000 |
400,985,000 |
0 |
- |
|
| ZTS |
Zoetis Inc. |
Director |
– • • |
2013-02-06 |
4 |
S |
$0.00 |
$0 |
D/D |
(99,015,000) |
0 |
0 |
- |
|
| ZTS |
Zoetis Inc. |
Director |
– • • |
2013-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,915,000 |
12,915,000 |
0 |
- |
|
| ZTS |
Zoetis Inc. |
Director |
– • • |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
86,100,000 |
|
- |
|
| ICGN |
Icagen Inc |
10% Owner |
– – • |
2011-09-02 |
4/A |
B |
$6.00 |
$27,671,526 |
I/I |
4,611,921 |
4,611,921 |
1.5 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
